Medical device innovator Cardiac Insight, Inc. has closed a $2.5 million
Series C capital funding. A University of Washington spinoff, the
privately-held company focuses on advanced cardiac and respiratory
sensing and computing technologies. Proceeds will be used to accelerate
the market penetration of the company’s CardeaScreen™ product and
finalize the development of the company’s proprietary wearable sensor
CardeaScreen helps identify young athletes who may be at risk for sudden
cardiac arrest (SCA). A 12-lead electrocardiogram (ECG) exam takes less
than 20 seconds. The company’s patented wireless hand-held device and
advanced analysis software then assists physicians to determine the need
for further evaluation prior to participation in strenuous activities.
“We are excited to have completed this funding and move forward with our
near term FDA submission for our 7-day ECG Monitor and increasing the
sales of our CardeaScreen 12-lead device. Cardiac Insights' shareholders
and our partners look forward to both products serving patients by the
end of 2016,” says Brad Harlow, CEO of the company.
CardeaScreen diagnostic algorithms have substantially reduced the rate
of false positive indications. This breakthrough makes the non-invasive
screening cost-effective for schools and is emerging as a best practice
for pre-participation examinations by pediatricians and family practice
Cardiac Insight is also engaged in the development of single-use,
patient-centric technologies to simplify and streamline complex
diagnostic exams centered around cardiology and related practices.
Further information is available online at www.cardiacinsightinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160429005255/en/